Erythropoietin for gastrointestinal dysfunction

Patent metadata

Field	Value
Publication number	US-10695402-B2
Application number	US-201815923275-A
Country	US
Kind code	B2
Filing date	Mar 16, 2018
Priority date	Mar 16, 2017
Publication date	Jun 30, 2020
Grant date	Jun 30, 2020

Abstract

This invention relates to treating gastrointestinal dysfunction with erythropoietin (EPO) or its analog.

First claim

What is claimed is:

1. A method for increasing intestinal motility in a mammal that has gastrointestinal dysmotility and does not have anemia, the method comprising administering to the mammal an effective amount of erythropoietin (EPO) or an analog thereof, wherein the analog comprises the sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO:4.

2. The method of claim 1 , wherein the subject mammal is suffering from a condition selected from the group consisting of an intestinal injury, an abdominal trauma, an intestinal inflammatory condition, an intestinal infection, slow transit constipation, post-operative ileus, a neurodegenerative injury, a neurotraumatic injury, a congenital problem, and a malnutrition-malabsorption problem.

3. The method of claim 2 , wherein the malnutrition-malabsorption problem is caused by one or more selected from the group consisting of an intestinal injury, an abdominal trauma, an intestinal inflammatory condition, an intestinal infection, constipation, post-operative ileus, a neurodegenerative injury, a neurotraumatic injury, a congenital problem, Gaucher disease, refeeding syndrome, extremely low birth weight infants, cancer cachexia, infection, cancer, spinal cord dysfunction, spinal dysraphism, bifida, tumor, central nervous system dysfunction, peripheral neuropathy, removal part of the gastrointestinal tract, hemorrhage, liver dysfunction, celiac disease, cystic fibrosis, muscular dystrophies, and cerebral palsy.

4. The method of claim 2 , wherein the congenital problem is selected from the group consisting of Gastroschisis, omphalocele, aganglionic megacolon, Hirschprung's disease, chronic intestinal pseudo-obstruction, small left colon syndrome, anorectal anomalies, esophageal dysplasia and atresias, ectopic anus, congenital hernias, and internal anal sphincter achalasia.

5. The method of claim 2 , wherein the condition is an intestinal inflammatory condition.

6. The method of claim 2 , wherein the constipation is caused by opiate use.

7. The method of claim 1 , wherein the mammal does not have acute uremia due to kidney failure.

8. The method of claim 1 , wherein the EPO or analog is administered as a conjugate.

9. The method of claim 8 , wherein the conjugate is a PEGylated erythropoietin or analog thereof.

10. The method of claim 1 , wherein the EPO or the analog thereof is administered at 100 to 1,000 U/kg.

11. The method of claim 10 , wherein the EPO or the analog thereof is administered at 200-500 U/Kg.

12. The method of claim 11 , wherein the EPO or the analog thereof is administered at 250-350 U/kg.

13. The method of claim 1 , wherein the mammal is a human.

14. The method of claim 1 , wherein the mammal is a non-human mammal.

15. The method of claim 1 , wherein the EPO or the analog is administered orally.

16. The method of claim 1 , wherein the EPO or the analog is administered by insertion, implantation or injection into the mammal.

17. The method of claim 1 , wherein the EPO or the analog is administered by subcutaneous injection or intravenous injection.

18. The method of claim 1 , comprising administering erythropoietin or the analog to the mammal over a treatment period of at least 24 hours.

19. The method of claim 18 , comprising administering erythropoietin or the analog to the mammal over a treatment period of 24 hours to years.

Assignees

• Univ Rochester

Inventors

• Elfar John
• Elfar Walaa
• Noble Mark

Classifications

• A61P1/14

  Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents · CPC title

• A61K38/1816 Primary

  Erythropoietin [EPO] · CPC title

• A61K47/60

  the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title